Patent intelligence · US
US 6248749
Use of inhibitors of the activity of retinoic acid for treating sensit ive skin and/or acute damage induced by UV radiation
Use of inhibitors of the activity of retinoic acid for treating sensit ive skin and/or acute damage induced by UV radiation
Patent details — US 6248749
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jun 19, 2001
- Expiration
- Jun 14, 2021
- Claims
- 7
- CPC classes
- A61K, A61K31/00, A61K31/192, A61K31/196
Quick answer
US 6248749 (Use of inhibitors of the activity of retinoic acid for treating sensit ive skin and/or acute damage induced by UV radiation) is held by Centre International de Recherches Dermatalogiques Galderma (C.I.R.D.) Galderma. Status: expired. Granted Jun 19, 2001. Expires Jun 14, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K31/00, A61K31/192, A61K31/196, A61K31/202, A61K31/382
More from Centre International de Recherches Dermatalogiques Galderma (C.I.R.D.) Galderma
Related pharmaceutical patents in our USPTO index.
-
US 12208123
Compositions and methods for the treatment of skin conditions
granted -
US 6759396
Compositions based on a synergistic mixture of at least one VDR ligand and a retinoid
expired -
US 6593359
Use of a RAR-&ggr;-specific agonist ligand for increasing the rate of apoptosis
expired -
US 6515021
Bicyclic aromatic compounds
expired -
US 6506796
Use of a RAR-&ggr;-specific agonist ligand for increasing the rate of apoptosis
expired -
US 6368608
Polyaromatic propynyl compounds and pharmaceutical/cosmetic compositions comprised thereof
expired -
US 6326510
Bi-aromatic compounds, compositions containing them and uses
expired -
US 6313162
Propynyl or dienyl biaromatic compounds
expired
Frequently asked questions
What is US patent 6248749?
US 6248749 (Use of inhibitors of the activity of retinoic acid for treating sensit ive skin and/or acute damage induced by UV radiation) is held by Centre International de Recherches Dermatalogiques Galderma (C.I.R.D.) Galderma. Status: expired. Granted Jun 19, 2001. Expires Jun 14, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6248749?
Centre International de Recherches Dermatalogiques Galderma (C.I.R.D.) Galderma is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 30 pharmaceutical patents for this assignee.
When does US 6248749 expire?
Our index shows an expiration date of Jun 14, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.